Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fcγ receptor type III, and Mannose-binding protein in febrile children with cancer and neutropenia

Clinical Infectious Diseases

Volumn 29, Issue 2, 1999, Pages 414-419

  Lehrnbecher, Th ^a,b,c,d   Venzon, D ^a,b,c   De Haas, M ^a,b,c   Chanock, S J ^a,b,c   Kuhl J ^a,b,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CENTRAL LABORATORY   (Netherlands)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FC RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; MANNOSE BINDING PROTEIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOOD LEVEL; CANCER PATIENT; CHILD; DISEASE SEVERITY; EARLY DIAGNOSIS; FEBRILE NEUTROPENIA; FEVER; FUNGUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

EID: 0032813989     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520224     Document Type: Article

References (43)

1. 1. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32.
2. 2. Rackoff WR, Gonin R, Robinson C, Kreissman SG, Breitfeld PB. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996;14:919-24.
3. 3. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
4. 4. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
5. 5. Schimpff SC, Young VM, Greene WH, et al. Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens. Ann Intern Med 1972;77:707-14.
6. 6. Chanock S. Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am 1993;7:771-94.
7. 7. Pizzo PA, Robichaud KJ, Wesley R, Commers JR. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore) 1982;61:153-65.
8. 8. Buchanan GR. Approach to the treatment of the febrile cancer patient with low-risk neutropenia. Hematol Oncol Clin North Am 1993;7:919-36.
9. 9. Chanock SJ. A review of antibacterial and antifungal therapy in the febrile child with neutropenia induced by antineoplastic therapy. Int J Pediatr Hematol Oncol 1998;4:459-72.
10. 10. Rose P, Johnson S, Meakin M, Mackie P, Stuart J. Serial study of C-reactive protein during infection in leukemia. J Clin Pathol 1981;34:263-6.
11. 11. Starke I, De Beer F, Donnelly J, et al. Serum C-reactive protein levels in the management of infection in acute leukaemia. Eur J Cancer Clin Oncol 1984;20:319-25.
12. 12. Abrahamsson J, Pahlman M, Mellander L. Interleukin 6, but not tumour necrosis factor-alpha, is a good predictor of severe infection in febrile neutropenic and non-neutropenic children with malignancy. Acta Paediatr 1997;86:1059-64.
13. 13. Heney D, Lewis IJ, Evans SW, et al. Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. J Infect Dis 1992;165:886-90.
14. 14. Peltola H, Jaakkola M. C-reactive protein in early detection of bacteremic versus viral infections in immunocompetent and compromised children. J Pediatr 1988;113:641-6.
15. 15. Riikonen P, Saarinen U, Teppo A, et al. Cytokine and acute-phase reactant levels in serum of children with cancer admitted for fever and neutropenia. J Infect Dis 1992;166:432-6.
16. 16. Santolaya ME, Cofre J, Beresi V. C-reactive protein: a valuable aid for the management of febrile children with cancer and neutropenia. Clin Infect Dis 1994;18:589-95.
17. 17. Katz JA, Mustafa MM, Bash RO, Cash JV, Buchanan GR. Value of C-reactive protein determination in the initial diagnostic evaluation of the febrile, neutropenic child with cancer. Pediatr Infect Dis J 1992;11:708-12.
18. 18. Engervall P, Granstrom M, Andersson B, Bjorkholm M. Monitoring of endotoxin, interleukin-6, and C-reactive protein serum concentrations in neutropenic patients with fever. Eur J Haematol 1995;54:226-34.
19. 19. Waage A, Steinshamm S. Cytokine mediators of septic infections in the normal and granulocytopenic host. Eur J Haematol 1993;50:243-9.
20. 20. Engel A, Kern W, Murdter G, Kern P. Kinetics and correlation with body temperature of circulating interleukin-6, interleukin-8, tumor necrosis factor alpha, and interleukin-1 beta in patients with fever and neutropenia. Infection 1994;22:160-4.
21. 21. Guenther G, Gardlund B, Hast R, et al. Endotoxaemia and inflammatory mediators in febrile patients with haemalological disease. J Intern Med 1995;237:27-33.
22. 22. Hynninen M, Valtonen M, Vaara M, et al. Plasma endotoxin and cytokine levels in neutropenic and non-neutropenic bacteremic patients. Eur J Clin Microbiol Infect Dis 1995;14:1039-45.
23. 23. Rintala E, Pulkki K, Mertsola J, Nevalainen T, Nikoskelainen J. Endotoxin, interleukin-6, and phospholipase-A2 as markers of sepsis in patients with hematological malignancies. Scand J Infect Dis 1995;27:39-43.
24. 24. Hynninen M, Valtonen M, Vaara M, et al. Plasma interleukin-8, interleukin-10, and E-selectin levels in neutropenic and non-neutropenic bacteremic patients. Eur J Clin Microbiol Infect Dis 1997;16:587-91.
25. 25. Lindemann A, Tamm I, Tanodi K, Mertelsmann R. Interleukin-8 serum levels for early detection of infectious episodes in neutropenic patients [letter]. J Infect Dis 1995;172:610.
26. 26. Waage A, Remick D, Steinshamn S, Deforge L, Lamvik J. Interleukin 8 in serum in granulocytopenic patients with infections. Br J Haematol 1994;86:36-40.
27. 27. Aittoniemi J, Rintala E, Miettinen A, Soppi E. Serum mannan-binding lectin (MBL) in patients with infections: clinical and laboratory correlates. APMIS 1997;105:617-22.
28. 28. Ezekowitz RA, Day LE, Herman GA. A human mannose-binding protein is an acute-phase reactant that shares sequence homology with other vertebrate lectins. J Exp Med 1988;167:1034-46.
29. 29. Arai T, Tabona P, Summerfield JA. Human mannose-binding protein gene is regulated by interleukins, dexamethasone, and heat shock. Q J Med 1993;86:575-82.
30. 30. Fleit HB, Kobasiuk CB, Doly C, et al. A soluble form of Fc-gamma-RIII is present in human serum and other body fluids and is elevated at sites of inflammation. Blood 1992;79:2721-8.
31. 31. Hommes DW, Meenan J, de Haas M, et al. Soluble Fc-gamma receptor III (CD16) and eicosanoid concentrations in gut lavage fluid from patients with inflammatory bowel disease: reflection of mucosal inflammation. Gut 1996;38:564-7.
32. 32. Huizinga T, de Haas M, Kleijer M, et al. Soluble Fc gamma receptor III in human plasma originates from release by neutrophils. J Clin Invest 1990;86:416-23.
33. 33. Koene H, De Haas M, Kleijer M, Roos D, Von dem Borne A. NA-phenotype-dependent differences in neutrophil Fc-gamma-receptor IIIb expression cause differences in plasma levels of soluble Fc-gamma-receptor III. Br J Haematol 1996;93:235-41.
34. 34. Super M, Gillies SD, Foley S, et al. Distinct and overlapping functions of allelic forms of human mannose binding protein. Nat Genet 1992;2: 50-5.
35. 35. Dofferhoff AS, Bom VJ, de Vries-Hospers HG, et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992;20:185-92.
36. 36. Lehrnbecher T, Foster C, Vazquez N, Mackall CL, Chanock SJ. Therapy-induced alterations in host defense in children receiving chemotherapy. J Pediatr Hematol Oncol 1997;19:399-417.
37. 37. Mackall C, Fleisher T, Brown M, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84: 2221-8.
38. 38. Miethke T, Wahl C, Heeg K, et al. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med 1992;175:91-8.
39. 39. Schumann RR. Function of lipopolysaccharide (LPS)-binding protein (LBP) and CD14, the receptor for LPS/LBP complexes: a short review. Res Immunol 1992;143:11-5.
40. 40. Hack CE, De Groot ER, Felt-Bersma RJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989;74:1704-10.
41. 41. Rubin M, Hathorn JW, Marshall D, et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30-5.
42. 42. Koene HR, de Haas M, Kleijer M, et al. Clinical value of soluble IgG Fc receptor type III in plasma from patients with chronic idiopathic neutropenia. Blood 1998;91:3962-6.
43. 43. Huizinga T, De Haas M, Van Oers M, et al. The plasma concentration of soluble Fc-gamma RIII is related to production of neutrophils. Br J Haematol 1994;87:459-63.